Acetaminophen Chlorpheniramine Maleate Jujube Frui

證據等級: L5

預測適應症: 0 個

ACETAMINOPHEN + CHLORPHENIRAMINE MALEATE + JUJUBE FRUIT: No Repurposing Prediction Available

One-Sentence Summary

This Evidence Pack covers a three-component combination product (acetaminophen, chlorpheniramine maleate, and jujube fruit) that is not currently marketed in any tracked regulatory database and carries no DrugBank ID on record. The TxGNN model returned no predicted indications for this combination, as the absence of a DrugBank ID prevents knowledge-graph embedding from generating disease-association scores. A meaningful repurposing evaluation cannot proceed without resolving the upstream data gaps identified below.

Quick Overview

Item	Content
Original Indication	No data available
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — no predictions returned
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on publicly known pharmacology, this product combines three distinct agents: acetaminophen (analgesic and antipyretic), chlorpheniramine maleate (first-generation antihistamine that blocks H₁ receptors), and jujube fruit (a traditional East Asian botanical with reported sedative, anxiolytic, and digestive properties). This profile is characteristic of OTC cold-and-allergy combination products found in East Asian markets, but no approved indication is on record in any regulatory database queried.

The TxGNN model relies on a DrugBank ID to anchor a drug node within the heterogeneous knowledge graph. Without that anchor, the model cannot compute drug–disease embedding distances and therefore returns an empty prediction set. This is a pipeline input failure, not a negative prediction result — it means the combination has not been evaluated, not that it has been found ineffective.

Because the combination also lacks a recognized INN entry as a single entity, it is possible that each component exists independently in DrugBank and that splitting the query would yield meaningful repurposing signals for each component separately.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This combination has no DrugBank ID, no market authorization, no TxGNN predictions, and no safety data on record — the minimum inputs required for a repurposing evaluation are all absent.

To proceed, the following is needed:

Resolve the DrugBank ID issue: Either locate an existing DrugBank entry for this specific combination, or split the query into three independent evaluations — DB00316 (acetaminophen), DB01114 (chlorpheniramine maleate), and a jujube fruit botanical entry — and re-run the TxGNN pipeline for each
Retrieve MOA data (DG002): Query DrugBank API individually for each component to reconstruct a composite mechanism profile
Retrieve safety data (DG001): Download and parse the package insert PDF from any market where this combination or its closest equivalent is authorized, to populate key warnings and contraindications
Verify brand identity: Search regulatory databases under alternative spellings, brand names, or Chinese INN equivalents to confirm whether this combination is registered under a different identifier
Re-run the evidence pipeline after the DrugBank ID is resolved to generate TxGNN predictions, clinical trial matches, and literature links
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.